Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20093 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HS-20093 + bevacizumab is a combination of two anticancer monoclonal antibody-based agents. HS-20093 is a B7-H3-targeted antibody-drug conjugate (ADC) consisting of a fully humanized anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload, primarily developed for advanced solid tumors, including small cell lung cancer and osteosarcoma[4][6][8]. Bevacizumab is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting tumor angiogenesis and growth[2][5][9]. This combination is being investigated for its potential to deliver both direct cytotoxicity via HS-20093’s ADC mechanism and antiangiogenic effects through bevacizumab in solid tumor treatment.
- Brand names
- AvastinAlymsysVegzelmaMvasiZirabev
- Other names
- GSK'227 + bevacizumabHS-20093 + bevacizumab
02
Targets
Beyond the preview
Go deeper on HS-20093 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20093 + bevacizumab.